PMID- 20371128
OWN - NLM
STAT- MEDLINE
DCOM- 20101116
LR  - 20221207
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 88
IP  - 3
DP  - 2010 Jun
TI  - Hydrochloride pioglitazone decreases urinary monocyte chemoattractant protein-1 
      excretion in type 2 diabetics.
PG  - 247-51
LID - 10.1016/j.diabres.2010.03.008 [doi]
AB  - AIM: To observe the effects of hydrochloride pioglitazone on monocyte 
      chemoattractant protein-1 (MCP-1) excretion in type 2 diabetics and explore its 
      reno-protective mechanism. METHODS: 98 uncontrolled type 2 diabetics with fasting 
      blood glucose (FBG) between 7.0 and 13.0 mmol/L and glycated hemoglobin A1c 
      (HbA1c)> or =7.0% were assigned randomly into group DP (pioglitazone add-on) and 
      group DS (sulfonylureas add-on). Another 49 healthy individuals were chosen as 
      normal controls (group NC). At the basal and 12th week, FBG, HbA1c, urinary 
      MCP-1, albumin (UALB) and creatinine (UCr) were determined. RESULTS: (1) Compared 
      with group NC, all the parameters mentioned above were significantly increased in 
      diabetic groups. (2) Compared with pre-treatment, FBG, HbA1c and urinary 
      MCP-1/UCr ratio (UMCR) were obviously decreased in both therapy groups; systolic 
      blood pressure (SBP), diastolic blood pressure (DBP) and UALB/UCr ratio (UACR) 
      decreased markedly in group DP (P<0.05 or P<0.01), while slightly in group DS 
      (P>0.05). (3) FBG and HbA1c had no marked difference between group DP and group 
      DS after treatment, however, SBP, DBP, UACR and UMCR in group DP were 
      significantly lower than those in group DS (P<0.05 or P<0.01). CONCLUSIONS: 
      Pioglitazone can decrease urinary albumin and MCP-1 excretion in type 2 
      diabetics, which may partly contribute to its reno-protection by inhibiting the 
      inflammation reaction in vivo.
CI  - Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
FAU - Ye, Shandong
AU  - Ye S
AD  - Department of Endocrinology, Anhui Provincial Hospital Affiliated to Anhui 
      Medical University, Lujiang Street, Hefei 230001, Anhui Province, China. 
      ysd6464@yahoo.com.cn
FAU - Zheng, Mao
AU  - Zheng M
FAU - Hu, Yuanyuan
AU  - Hu Y
FAU - Wu, Fengzhen
AU  - Wu F
FAU - Zhao, Lili
AU  - Zhao L
FAU - Chen, Yan
AU  - Chen Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100403
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Chemokine CCL2)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazolidinediones)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Chemokine CCL2/*urine
MH  - Diabetes Mellitus, Type 2/*drug therapy/pathology/*urine
MH  - Diabetic Nephropathies/*prevention & control
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pioglitazone
MH  - Thiazolidinediones/*therapeutic use
MH  - Treatment Outcome
EDAT- 2010/04/08 06:00
MHDA- 2010/11/17 06:00
CRDT- 2010/04/08 06:00
PHST- 2009/12/13 00:00 [received]
PHST- 2010/02/24 00:00 [revised]
PHST- 2010/03/08 00:00 [accepted]
PHST- 2010/04/08 06:00 [entrez]
PHST- 2010/04/08 06:00 [pubmed]
PHST- 2010/11/17 06:00 [medline]
AID - S0168-8227(10)00132-4 [pii]
AID - 10.1016/j.diabres.2010.03.008 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2010 Jun;88(3):247-51. doi: 
      10.1016/j.diabres.2010.03.008. Epub 2010 Apr 3.